BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo in AChR seronegative generalized myasthenia gravis expands the label to all MG serotypes and expands the U.S. addressable patient population by about 11,000, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Myles Minter Reiterates Buy as Vyvgart’s Expanded FDA Label and Attractive Valuation Support Continued Growth
- Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
- Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
- Argenx price target raised to $1,135 from $1,120 at Guggenheim
- Argenx price target raised to $1,260 from $1,247 at Wells Fargo